骨肉瘤血管新生的研究进展  

Research progress on angiogenesis in osteosarcoma

作　　者：韩中玮 任可[2] HAN Zhongwei;REN Ke(Medicine School of Southeast University,Nanjing 210009,China)

机构地区：[1]东南大学医学院,南京210009 [2]东南大学附属中大医院骨科,210009

出　　处：《临床肿瘤学杂志》2024年第12期1241-1246,共6页Chinese Clinical Oncology

基　　金：国家自然科学基金资助项目(82272701)。

摘　　要：骨肉瘤常见于青少年,早期诊断困难,易发生转移,预后较差。血管新生过程为骨肉瘤的生长侵袭提供了养分并促进其远处转移,显著影响了骨肉瘤的恶性程度。以血管新生过程的各环节为靶点开发抗血管生成药物是近年来研究的热点,但血管新生过程复杂且调控因子众多,骨肉瘤组织对靶向药物易产生耐药性,所以目前骨肉瘤的抗血管新生疗效仍不理想。本文综述近年来骨肉瘤血管新生的相关热点调控因子,以为抗血管新生药物靶点的选择和临床诊疗提供参考。Osteosarcoma is common in adolescents,with difficulty in early diagnosis,high risk of metastasis,and poor prognosis.The process of angiogenesis provides nutrients for the growth and invasion of osteosarcoma and promotes distant metastasis,significantly affecting its malignant potential.The development of anti-angiogenic drugs targeting various aspects of the angiogenesis process has been a hot topic in recent years.However,the angiogenesis process is complex and regulated by numerous factors,and osteosarcoma tissues are prone to developing resistance to targeted drugs.Therefore,the current anti-angiogenic efficacy of osteosarcoma is still not ideal.This article reviews the hot regulatory factors related to angiogenesis in osteosarcoma in recent years,aiming to provide a reference for the selection of anti-angiogenic drug targets and clinical diagnosis and treatment.

关 键 词：骨肉瘤 肿瘤血管生成 抗血管生成治疗 血管内皮生长因子 肿瘤微环境 

分 类 号：R738.1[医药卫生—肿瘤]